Literature DB >> 22047502

Re-examination of the dimerization state of leucine-rich repeat kinase 2: predominance of the monomeric form.

Genta Ito1, Takeshi Iwatsubo.   

Abstract

Mutations in the LRRK2 (leucine-rich repeat kinase 2) gene have been identified in PARK8, a major form of autosomal-dominantly inherited familial Parkinson's disease, although the biochemical properties of LRRK2 are not fully understood. It has been proposed that LRRK2 predominantly exists as a homodimer on the basis of the observation that LRRK2, with a theoretical molecular mass of 280 kDa, migrates at 600 kDa (p600 LRRK2) on native polyacrylamide gels. In the present study, we biochemically re-examined the nature of p600 LRRK2 and found that p600 LRRK2 was fractionated with a single peak at ~272 kDa by ultracentrifugation on a glycerol gradient. In addition, p600 LRRK2 behaved similarly to monomeric proteins upon two-dimensional electrophoretic separation. These results suggested a monomeric composition of p600 LRRK2 within cells. The p600 LRRK2 exhibited kinase activity as well as GTP-binding activity, and forced dimerization of LRRK2 neither upregulated its kinase activity nor altered its subcellular localization. Collectively, we conclude that the monomer form of LRRK2 is predominant within cells, and that dimerization is dispensable for its enzymatic activity.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22047502     DOI: 10.1042/BJ20111215

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  23 in total

1.  Membrane recruitment of endogenous LRRK2 precedes its potent regulation of autophagy.

Authors:  Jason Schapansky; Jonathan D Nardozzi; Fredrik Felizia; Matthew J LaVoie
Journal:  Hum Mol Genet       Date:  2014-03-27       Impact factor: 6.150

2.  The G2385R variant of leucine-rich repeat kinase 2 associated with Parkinson's disease is a partial loss-of-function mutation.

Authors:  Iakov N Rudenko; Alice Kaganovich; David N Hauser; Aleksandra Beylina; Ruth Chia; Jinhui Ding; Dragan Maric; Howard Jaffe; Mark R Cookson
Journal:  Biochem J       Date:  2012-08-15       Impact factor: 3.857

Review 3.  LRRK2 Pathways Leading to Neurodegeneration.

Authors:  Mark R Cookson
Journal:  Curr Neurol Neurosci Rep       Date:  2015-07       Impact factor: 5.081

4.  Number and brightness analysis of LRRK2 oligomerization in live cells.

Authors:  Nicholas G James; Michelle A Digman; Enrico Gratton; Barbara Barylko; Xiaodong Ding; Joseph P Albanesi; Matthew S Goldberg; David M Jameson
Journal:  Biophys J       Date:  2012-06-05       Impact factor: 4.033

Review 5.  LRRK2 GTPase dysfunction in the pathogenesis of Parkinson's disease.

Authors:  Yulan Xiong; Valina L Dawson; Ted M Dawson
Journal:  Biochem Soc Trans       Date:  2012-10       Impact factor: 5.407

Review 6.  Leucine-rich repeat kinase 2 (LRRK2) as a potential therapeutic target in Parkinson's disease.

Authors:  Byoung Dae Lee; Valina L Dawson; Ted M Dawson
Journal:  Trends Pharmacol Sci       Date:  2012-05-09       Impact factor: 14.819

Review 7.  The neurobiology of LRRK2 and its role in the pathogenesis of Parkinson's disease.

Authors:  Hardy J Rideout; Leonidas Stefanis
Journal:  Neurochem Res       Date:  2013-06-01       Impact factor: 3.996

8.  The C-Terminal Domain of LRRK2 with the G2019S Substitution Increases Mutant A53T α-Synuclein Toxicity in Dopaminergic Neurons In Vivo.

Authors:  Noémie Cresto; Camille Gardier; Marie-Claude Gaillard; Francesco Gubinelli; Pauline Roost; Daniela Molina; Charlène Josephine; Noëlle Dufour; Gwenaëlle Auregan; Martine Guillermier; Suéva Bernier; Caroline Jan; Pauline Gipchtein; Philippe Hantraye; Marie-Christine Chartier-Harlin; Gilles Bonvento; Nadja Van Camp; Jean-Marc Taymans; Karine Cambon; Géraldine Liot; Alexis-Pierre Bemelmans; Emmanuel Brouillet
Journal:  Int J Mol Sci       Date:  2021-06-23       Impact factor: 5.923

9.  Biochemical characterization of highly purified leucine-rich repeat kinases 1 and 2 demonstrates formation of homodimers.

Authors:  Laura Civiero; Renée Vancraenenbroeck; Elisa Belluzzi; Alexandra Beilina; Evy Lobbestael; Lauran Reyniers; Fangye Gao; Ivan Micetic; Marc De Maeyer; Luigi Bubacco; Veerle Baekelandt; Mark R Cookson; Elisa Greggio; Jean-Marc Taymans
Journal:  PLoS One       Date:  2012-08-29       Impact factor: 3.240

10.  GTP binding and intramolecular regulation by the ROC domain of Death Associated Protein Kinase 1.

Authors:  Joseph D Jebelli; Sybille Dihanich; Laura Civiero; Claudia Manzoni; Elisa Greggio; Patrick A Lewis
Journal:  Sci Rep       Date:  2012-09-26       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.